Consensus document of the Spanish Society of Arteriosclerosis (SEA) for the prevention and treatment of cardiovascular disease in type 2 diabetes mellitus.

Autor:	Ruiz-García A; Centro de Salud Universitario Pinto, Unidad de Lípidos y Prevención Cardiovascular, Universidad Europea de Madrid, Pinto, Madrid, España., Arranz-Martínez E; Centro de Salud San Blas, Parla, Madrid, España., Morón-Merchante I; Centro de Salud Universitario Goya, Universidad Autónoma de Madrid, Madrid, España., Pascual-Fuster V; Centro de Salud Palleter, Universidad CEU-Cardenal Herrera, Castellón, España. Electronic address: pascual_vic@gva.es., Tamarit JJ; Consorcio Hospital General Universitario, Valencia, España., Trias-Villagut F; Hospital de Bellvitge, Universitat de Barcelona, Barcelona, España., Pintó-Sala X; Hospital de Bellvitge, Universitat de Barcelona, Barcelona, España., Ascaso JF; Hospital Clínico-Universitat de València, INCLIVA Research Institute, CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), ISCIII, Valencia, España.
Jazyk:	English; Spanish; Castilian
Zdroj:	Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis [Clin Investig Arterioscler] 2018 Jul; Vol. 30 Suppl 1, pp. 1-19.
DOI:	10.1016/j.arteri.2018.06.006
Abstrakt:	A consensus document of the Diabetes working group of the Spanish Society of Arteriosclerosis (SEA) is presented, based on the latest studies and conceptual changes that have appeared. It presents the cardiovascular risk in type 2 diabetes mellitus (T2DM) and the action guidelines for the prevention and treatment of cardiovascular disease (CVD) associated with T2DM. The importance of lipid control, based on the objective of LDL-C and non-HDL-C when there is hypertriglyceridemia, and the blood pressure control in the prevention and treatment of CVD is evaluated. The new hypoglycemic drugs and their effects on CVD are reviewed, as well as the treatment and control guidelines of hyperglycemia. Likewise, the use of antiplatelet agents is considered. Emphasis is placed on the importance of global and simultaneous action on all risk factors to achieve a significant reduction in cardiovascular events. This supplement is sponsored by Laboratorios Esteve, S.A. (Copyright © 2018 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu